Sufugolix

Sufugolix

SCHEMBL4251869

CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1.Cl

nearest known ligand 0.99

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GNRHR

The experimentally established mechanism targets of Sufugolix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GNRHR known ✓ P30968 20/20 0.99

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sufugolix SCHEMBL209021 0.99 GNRHR (1.00) GNRHR
SCHEMBL782109 0.96 GNRHR (0.93) GNRHR
SCHEMBL6646325 0.95 GNRHR (0.92) GNRHR
SCHEMBL780108 0.95 GNRHR (0.92) GNRHR
SCHEMBL779784 0.94 GNRHR (1.00) GNRHR
SCHEMBL778228 0.93 GNRHR (0.88) GNRHR
SCHEMBL6646171 0.92 GNRHR (0.86) GNRHR
Hydrochloric Acid SCHEMBL6644800 0.92 GNRHR (0.99) GNRHR
SCHEMBL4885456 0.92 GNRHR (0.86) GNRHR
SCHEMBL779746 0.92 GNRHR (1.00) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917978-B1 Premature ovulation preventive agent TAKEDA PHARMACEUTICAL (JP) 2014-08-20 EP disclosed
US-20090048273-A1 PREMATURE OVULATION PREVENTIVE AGENT TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
EP-1163244-B1 THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-03-10 EP disclosed
EP-1393747-A1 PREVENTIVES/REMEDIES FOR ALZHEIMER'S DISEASE Takeda Chemical Industries, Ltd. (JP) 2004-03-03 EP disclosed
US-20030134863-A1 Preventives/remedies for alzheimer's disease TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-17 US disclosed
US-6340686-B1 GONADOTROPIN-RELEASING HORMONE ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-01-22 US disclosed
US-6297379-B1 GONADOTROPIN RELEASING HORMONE (GNRH, SOMETIMES CALLED LH-RH (LUTEINIZING HORMONE RELEASING HORMONE)) ANTAGONIZING ACTIVITY, TREATING SEX HORMONE-DEPENDENT DISEASES. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134863-A1 Preventives/remedies for alzheimer's disease ACHE, GNRHR, PSEN1 GNRHR 2/4885
US-20090048273-A1 PREMATURE OVULATION PREVENTIVE AGENT GNRHR, FSHR, LHCGR GNRHR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.